We are using cookies This website uses cookies in order to offer you the most relevant information. By browsing this website, you accept these cookies.
Ovarian suppression may be administered with either tamoxifen or an aromataseinhibitor.
2
We postulated that an aromataseinhibitor would be safer and more effective.
3
The clinical usefulness of this new aromataseinhibitor remains to be studied further.
4
Multivariable logistic regression analysis examined temporal associations and characteristics associated with aromataseinhibitor use.
5
Despite providing substantial improvements in patient outcome, aromataseinhibitor resistance remains a major clinical challenge.
6
Additional studies were performed in WT mice treated with the aromataseinhibitor fadrozole or vehicle.
7
We found a potent aromataseinhibitor through the screening of agents for estrogen-dependent breast cancer.
8
These include androgen-deprivation therapy for prostate cancer and aromataseinhibitor therapy for breast cancer, among others.
9
Furthermore, GDNF-RET signaling promoted the survival of aromataseinhibitor-resistant cells and elicited resistance in aromataseinhibitor-sensitive cells.
10
Recent findings: Oestrogen-deprivation therapy in the form of the aromataseinhibitor letrozole has demonstrated activity in three clinical studies.
11
No correlation was observed between aromatase or COX-2 expression and the response of the patients to aromataseinhibitor treatment.
12
During therapy with the Gn-RH analogue, patients who had a positive ER status after chemotherapy received an aromataseinhibitor.
13
If they are newly diagnosed we are using an aromataseinhibitor instead of tamoxifen, she said in a statement.
14
We validated these findings by showing increased RET protein expression levels in an independent cohort of aromataseinhibitor-resistant patient specimens.
15
The metabolism of the steroidal aromataseinhibitor atamestane was studied in the rat, the cynomolgus monkey and in the human.
16
In breast cancer cells in two-dimensional and three-dimensional culture, GDNF-mediated RET signaling is enhanced in a model of aromataseinhibitor resistance.